-
Simnotrelvir Tablets/Ritonavir Tablets(co-packaged) and Deuremidevir Hydrobromide Tablets for treating COVID-19 infection approved for marketing with conditions
2023-01-29
Recently, the class 1 innovative drug Simnotrelvir Tablets/Ritonavir Tablets(co-packaged) (Chinese trade name: 先诺欣) of Simcere Pharmaceutical Group Limited and Deuremidevir Hydrobromide Tablets (Chinese trade name: 民得维) of Shanghai Wangshi Biomedicine Technology Inc. are approved for marketing with conditions by China NMPA through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
-
Second Biosimilar Tocilizumab Injection approved for marketing
2023-01-18
Recently, the Tocilizumab Injection (Chinese trade name: 安维泰) of Livzon Pharmaceutical Group Inc. is approved for marketing by China NMPA. This drug is the second Tocilizumab Injection biosimilar approved in China, which is indicated for rheumatoid arthritis.
-
Biosimilar Tocilizumab Injection approved for marketing
2023-01-16
Recently, the Tocilizumab Injection (Chinese trade name:施瑞立) of Bio-Thera Solutions, Ltd. is approved for marketing by China NMPA.
-
Mobocertinib succinate capsules approved for marketing with conditions
2023-01-11
Recently, the Class 1 innovative drug mobocertinib succinate capsule (trade name: 安卫力/EXKIVITY) of Takeda Pharmaceutical, Inc. is approved for marketing with conditions through the priority review and approval procedure by China NMPA.
-
Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing
2023-01-04
Recently, the innovative drug Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (trade name:复邦德) of Jiangsu Aidea Pharmaceutical Co., Ltd. is approved by China NMPA.
-
Importation of MSD's Molnupiravir Capsules approved with condition
2022-12-30
The importation registration of Molnupiravir Capsules (trade name: 利卓瑞/LAGEVRIO) for the treatment of COVID-19 of MSD Inc. is approved with condition for marketing by China NMPA on December 29, through emergency review and approval procedure in accordance with the relevant provisions of special review and approval prescribed in the Drug Administration Law.
